Hitachi High-Technologies signed a joint research agreement with Japan's National Cancer Center to develop a commercially viable method of blood diagnosis based on proteome analysis.

Hitachi High-Technologies signed a joint research agreement with Japan's National Cancer Center to develop a commercially viable method of blood diagnosis based on proteome analysis, including the development of blood specimen preprocessing technologies and the development of a general purpose MS system for clinical testing.